Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low ...
Neoadjuvant intralesional daromun (L19IL2/L19TNF) in resectable locally advanced melanoma: An update on the primary outcome and sensitivity analyses (EFS) from the PIVOTAL phase 3 trial. Late-stage ...
Genomic and transcriptomic correlates of HER3 expression in prostate cancer. Effect of GLP1-1RA exposure compared to DPP-4i exposure on progression of stage I-III cancer to stage IV cancer.
My NIH-funded research has been accepted by JCO Journals. Now what? If your article is Open Access: JCO Journals will deposit all open access articles to PubMed Central on behalf of the authors. If ...
The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
Plasma-guided adaptive first-line chemoimmunotherapy for non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full ...
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish The following represents disclosure ...
Neoadjuvant Immunotherapy for Colorectal Cancer: Too Good to Be True? Despite significant progress and improving outcomes in the management of plasma cell disorders, AL amyloidosis remains ...
Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary ...
Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) ...
Standard of Care in Hormone Receptor–Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools? Cutaneous melanoma remains the most lethal of the primary ...
Supported in part by the National Cancer Institute of the National Institutes of Health (Grant No. K08CA234225, G.R.W.), the American Cancer Society (Grant No. ACS-18-162-59-IRG, G.R.W.) and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results